IJSRST162422 | Received : 22 July 2016 | Accepted : 02 August 2016 | July-August 2016 [(2)4: 155-161 ] © 2016 IJSRST | Volume 2 | Issue 4 | Print ISSN: 2395-6011 | Online ISSN: 2395-602X Themed Section: Science and Technology 155 Treatment of Haemophilia A by Replacement Therapy using Factor VIII Inhibitors Maria Shahid, Sikander Ali Institute of Industrial Biotechnology (IIB), GC University Lahore, Pakistan ABSTRACT Haemophilia A is a very severe disease which is caused due to deficiency of a protein clotting factor VIII. Haemophilia A is X-linked recessive disorder which can be treated by the replacement therapy or by development of an inhibitors or antibodies against the FVIII. Hemarthroses is a disease in which bleeding in the joint spaces occur. This disease occurs approximately 70 to 80% in haemophilic patients. Then here we review about the epidimicity that deals with the transformation of haemophilia A. Then the process of inhibition stated, in which under the influence of some chemical substances the specific chemical process may inhibit. So, different replacement therapy may be ineffective when an inhibitor affect the factor Vǀǀǀ gene. In the end here stated different treatments for the management & control of disease, so among them the counselling between physician & patient is very effective. Keywords : Hemarthroses, Haemophilia, Epidimicity, Epidemiology, DNA, AVD, IgG, TCR, Arthropathy, Prophylaxis I. INTRODUCTION There are many different types of bleeding disorders in which haemophilia A is known as a result of the deficiency of the protein clotting factor VIII and is genetically severe bleeding disorder. The deficiency of factor VIII in 1 in every 5000 male births without racial majority as X-linked recessive abnormality (Soucie et al., 1998). Haemophilia A, as the most common disorder in patients, is intra-articular hemorrhages. The cure of haemophilia started from the last 40 years. In history, patients of haemophilia, including adults and children, had no ability of survival but now days this disease can be controlled and helps the patients to do their work activities in efficient way (DiMichele & Neufeld, 1998). Proper treatment of these patients requires deeply understanding of AHA path physiology by anaesthesiologists. There are different therapeutic treatments for other bleeding disorders so that haemophilia A also cured by specific medication and blood products. At present the best treatment of haemophilia A is to replace the factor VIII by using the plasma or recombinant FVIII in order to stable its homeostasis. When a patient is develop an inhibitor against the factor VIII then the replacement therapy of haemophilia A becomes hopeless. Now a day’s development of the inhibitor is the most important treatment of haemophilic patient (Fig. 1). Although there is decrease in death rate due to improvement in homeostatic agent but still there is another complication that is high rate of bleeding (Gringeri et al., 2003; Darby et al., 2004; Morfini et al., 2007; Brown et al., 2009; Di Minno et al., 2010). Figure 1. Difference between a normal and haemophilic blood vessel